Autonomous AI
Biopharma Foundry

View More

Monthly
Key Achievements

  • 2026-09-20Exploring the Future of AI-Driven Drug Discovery | Toursynbio Joins the “New Horizons, Intelligent Connections” Biopharma Ecosystem Forum
  • 2026-09-20Toursynbio @ Cambridge Tech Week 2026 | Connecting AI-Driven Biotech Innovation in Cambridge
  • 2026-09-18Toursynbio at the 2026 Minhang Biopharmaceutical Ecosystem Promotion Conference | Sharing Our Latest Practices in AI-Driven Biologics R&D
  • 2026-09-18Great News | Toursynbio Wins the “Industrial Value Award” at the 6th “Shanghai Global Talents Innovation & Entrepreneurship Competition
  • 2026-09-17Repost | The “Shanghai Global Talents Innovation & Entrepreneurship Competition” Competition Launches Its First AI4S Special Track, as AI Begins to “Read” the Source Code of Life
  • 2026-09-17Repost | A Practical Breakdown of AI Use Cases When AI Meets GMP Regulations: Compliance Challenges and Enterprise Implementation from a Quality Perspective

Introduction

Toursynbio is an AI-native biopharmaceutical company dedicated to building an Autonomous AI Biopharma Foundry and transforming drug discovery into drug creation. By integrating artificial intelligence with automated experimentation, Toursynbio is redefining how biologic medicines are designed, validated, and developed.

At the core of the company’s innovation is its proprietary ToursynClaw Scientific Superintelligent Agent Platform for biologics. The platform powers a closed-loop R&D engine that seamlessly connects AI-driven molecular design, automated wet-lab validation, and continuous data feedback, creating a self-improving development cycle. Using this integrated workflow, antibody design and functional validation can be completed in as little as 1.5 months.

To date, Toursynbio has advanced 16 antibody programs through PCC-stage validation within six months and generated leading experimental results against highly challenging targets, including GPCRs and intrinsically disordered protein regions. As one of the few biotechnology companies in China to fully integrate AI computing with automated laboratory infrastructure, Toursynbio is building an AI-powered biologics foundry that accelerates therapeutic innovation and establishes a new paradigm for biopharmaceutical R&D.

Challenge

Scientific Superintelligence Agents

Scientific Superintelligence Agents

Scientific superintelligence agents integrate foundation models, domain-specific tools, autonomous reasoning, and experimental feedback. By connecting molecular design, experimental validation, and iterative optimization in one workflow, they accelerate scientific discovery and biopharmaceutical R&D.

Dry-Wet Iterative Laboratory

Dry-Wet Iterative Laboratory

Our integrated computational–experimental laboratory connects design with validation, creating a closed loop of testing, data feedback, and model iteration to accelerate candidate discovery and optimization.

De Novo Design

De Novo Design

Starting from target structures and functional requirements, our de novo design technology generates functional proteins with novel sequences and structures, providing new molecular solutions for complex and traditionally difficult-to-drug targets.

Team

Toursynbio team gathering
Toursynbio at BIO International Convention
Toursynbio team gathering
Toursynbio at an industry exhibition
Toursynbio at BIO International Convention
Toursynbio founder speaking
Toursynbio at an industry exhibition
Toursynbio laboratory collaboration

Toursynbio is committed to accelerating R&D of scientific products through superintelligent technology, with applications in novel design of biological and material products.

Meet Our Team